Alnylam, Dharmacon, CytRx

Jan 05, 2006

Premium

Alnylam Licenses Kreutzer-Limmer IP to Dharmacon

Alnylam Pharmaceuticals said this week that it has granted Dharmacon a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family.

Specific terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Pushed Aside

The New York Times Magazine examines gender discrimination at the Salk Institute.

Dismissals at MD Anderson

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

Looking Into It

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

This Week in PLOS

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.

Featured White Papers

The WOLF 'Cuts' Time from CRISPR Workflows

Controlling Ribonuclease (RNase) with High Irradiance UV LED Light Engines

The Ultimate Guide to Mouse Clinical Trials

High Throughput RT-qPCR for Gene Expression Analysis

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

21

Featured Webinar

Implementation of qPCR Mutation Assays for Routine Use in a Hematology/Oncology Lab

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.

Menu